HUMAN PAPILLOMAVIRUS VACCINATION IN LOW-RESOURCE SETTINGS – OVERCOMING BARRIERS TO IMPLEMENTATION

Introduction: Human Papillomavirus (HPV) vaccination is a proven strategy for preventing cervical cancer and other HPV-related malignancies. Despite its efficacy, vaccine uptake remains low in low- and middle-income countries due to financial, cultural, and infrastructural barriers. High-income nations have achieved high coverage through national immunization programs, but many resource-limited settings still struggle. This study examines the key obstacles to HPV vaccination in six low-resource countries while exploring successful strategies to improve implementation. Aim: This study aims to identify barriers to HPV vaccination in resource-limited settings and propose evidence-based strategies to increase coverage. By analyzing vaccination trends across different economic settings, this research highlights interventions that can enhance HPV immunization programs. Materials and Methods: This study analyzed HPV vaccination data and policies (2000–2024) across six countries, with a case study from Uzbekistan’s School No. 38 highlighting implementation success. Ethical approval was obtained for a local survey. Results: Cost remains a significant barrier, with HPV vaccines priced at $75 per dose in India and Pakistan, rendering them inaccessible for many. In contrast, high-income countries like Australia and the UK offer free vaccinations, achieving coverage rates exceeding 70%. Vaccine hesitancy further restricts uptake, particularly in Russia, where anti-vaccine sentiment prevails, and Pakistan, where cultural and religious beliefs influence decision-making. Disparities in healthcare infrastructure also impact vaccine accessibility; Ukraine’s political instability disrupts immunization efforts, while Sri Lanka and Uzbekistan continue expanding programs despite logistical challenges.A school-based vaccination program at "OROM" General Secondary School No. 38 in Uzbekistan serves as an effective model. Among 18 girls aged 9 to 10 years, 17 received the first dose in March 2024, and 15 completed the second dose at school, while two received it at a local healthcare centre. One student remained unvaccinated due to illness. The government-funded program reported no adverse effects, demonstrating that school-based immunization campaigns can enhance HPV vaccination rates in resource-limited settings.Low-income countries like Rwanda and Bhutan have achieved coverage rates exceeding 90% through government funding and international partnerships. Upper-middle-income nations such as Brazil and South Africa show moderate progress but face challenges with rural access. Clinical studies confirm that HPV vaccination reduces cervical cancer incidence by more than 50% and significantly lowers rates of genital warts and other HPV-related malignancies. The vaccine provides cross-protective immunity, safeguarding against multiple HPV strains. Double-blind randomized trials confirm long-term efficacy, with no serious adverse effects reported. Conclusions: HPV vaccination is a highly effective and cost-efficient strategy for reducing cervical cancer and HPV-related diseases, yet financial, cultural, and healthcare infrastructure challenges continue to hinder its widespread adoption. School-based programs, government subsidies, and public awareness initiatives have proven successful in improving vaccination rates. Countries must adopt evidence-based strategies, leverage international funding, and strengthen healthcare systems to achieve the World Health Organization’s goal of 90% HPV vaccination coverage by 2030.